Ensysce Biosciences (ENSC) Short Interest Ratio & Short Volume

Short interest is the volume of Ensysce Biosciences shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 134,900 shares of ENSC short. 11.21% of Ensysce Biosciences' shares are currently sold short. Learn More on Ensysce Biosciences' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ensysce Biosciences: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.21% of Ensysce Biosciences' floating shares are currently sold short.

Ensysce Biosciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 134,900 shares, an increase of 328.3% from the previous total of 31,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

11.21% of Ensysce Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Ensysce Biosciences: Traws Pharma, Inc. (2.06%), HCW Biologics Inc. (1.33%), Kiora Pharmaceuticals, Inc. (1.16%), Talphera, Inc. (1.13%), Ainos, Inc. (86.75%), Acurx Pharmaceuticals, Inc. (2.15%), BioCardia, Inc. (1.08%), Aprea Therapeutics, Inc. (1.25%), Carisma Therapeutics, Inc. (1.60%), PharmaCyte Biotech, Inc. (0.35%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling ENSC is an investing strategy that aims to generate trading profit from Ensysce Biosciences as its price is falling. ENSC shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Ensysce Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENSC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENSC, twice per month. The most recent reporting period available is April, 15 2025.